Skip to Main Content
DownloadHi-Res Photo

Daniel P. Petrylak, MD

Professor of Medicine (Medical Oncology) and of Urology; Co-Leader, Cancer Signaling Networks, Yale Cancer Center

Contact Information

Daniel P. Petrylak, MD

Mailing Address

  • Medical Oncology

    PO Box 208032

    New Haven, CT, 06520-8032

    United States

Related Links

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

He has authored more than 100 peer-reviewed articles and book chapters on prostate and bladder cancer research outcomes.

Specialized Terms: Clinical trials for prostate and bladder cancers

Research Interests

Urinary Bladder Neoplasms; Medical Oncology; Prostatic Neoplasms; Urology; Signal Transduction; Clinical Trial

Clinical Trials

ConditionsStudy Title
ProstateA Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)
ProstateA Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
Other Urinary; Urinary BladderA Phase II Trial of Pembrolizumab and Ramucirumab in Patients With Progressive Transitional Cell Carcinoma After Treatment With an Immune Checkpoint Inhibitor
Urinary BladderA Pilot Study of Tazemetostat and MK-3475 (Pembrolizumab) in Advanced Urothelial Carcinoma
Other UrinaryA Phase 2 Study of Sitravatinib in Combination With Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma
ProstatePhase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Urinary BladderPhase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806)
ProstatePhase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With Small Cell Neuroendocrine Prostate Cancer
Prostate; Phase IA Phase 1, Open-label, Dose Escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-110 in Patients With Metastatic Castration-resistant Prostate Cancer Who Have Progressed on at Least Two Prior Systemic Therapies.
Other Urinary; Urinary BladderPhase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy
Other Urinary; Urinary BladderPhase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation
Other Urinary; Urinary BladderA Phase 1b Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Immune Checkpoint Inhibitor (CPI) Therapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer
Anus; Colon; Esophagus; Kidney; Lip, Oral Cavity and Pharynx; Lung; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Stomach; Thyroid; Unknown Sites; Breast; Urinary BladderDART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Anus; Bones and Joints; Brain and Nervous System; Breast - Female; Breast - Male; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Hodgkin's Lymphoma; Kaposi's sarcoma; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Lymphoid Leukemia; Melanoma, skin; Non-Hodgkin's Lymphoma; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Cervix; Urinary BladderNCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
Corpus Uteri; Other Female GenitalA Phase II Evaluation of Afatinib
Edit Profile